View this informative infographic containing numerous statistics about influenza in the U.S.

To help you manage effectively through the intricacies of 340B, Manatt Health has developed a 50-state survey on 340B, analyzing how states reimburse 340B covered entities and contract pharmacies for 340B drugs, and the steps states are taking to avoid duplicate discounts. D … Read More »

“Behavioral science” is becoming a buzzword for pharma. Why? Because behavior is a barrier to meeting brand objectives. This barrier could be in the form of a patient’s adherence, a patient’s reluctance to start a new therapy, or even a healthcare provider’s clinical inertia … Read More »

This white paper provides critical information about obstacles to continued oncology research and recommendations for effectively overcoming them. It first traces current and projected trends in the field of oncology and related market research. Next it presents key findings … Read More »

Data from clinical trials is extremely valuable but often underutilized. This is typically the result of insufficient planning. Industry experts are frustrated knowing that stakeholders do not have sufficient access to their data, thus losing tremendous value since the data … Read More »

Storytelling may seem like an antiquated tool in modern times, which is exactly what makes it so powerful. How? Life unfolds in the narratives we share with each other. A great story can go where quantitative analysis often cannot: straight to the heart. Clinical trial data … Read More »

This white paper explores how some of the world’s most innovative companies are bringing the patient experience front and centre in clinical trials, and reaping the benefits of doing so. From protocol design to recruitment and retention, it’s about seeing every touchpoint th … Read More »

In revolutions past, there have been moments when a seemingly singular entity or action emerges spontaneously and changes the existing course of action. But more often, it is multiple factors that coincide and work in tandem to comprehensively transform an entire industry or … Read More »

Sharp rises in opioid abuse and overdose rates in the United States over the past two decades have prompted much-needed review of prescription rates and ease of access to controlled substances.  Combatting these alarming trends requires assessing which opioids are more addic … Read More »

The way site feasibility is conducted has changed over the years. The practice of mailing paper questionnaires and manually reviewing paper results is obsolete — even emailing surveys has become outdated. Sponsors have transitioned to cloud-based, site feasibility solutions … Read More »

In the pharmaceutical world, the sales representative’s role interacting with HCPs—and their impact on those HCPs—has taken a hit. KOL interactions remain critically important to ensure HCP audiences receive the right message via the right channel at the right time. Take a f … Read More »

The incidences of pharmacy fraud involving pharmaceutical manufacturers’ co-pay card programs are on the rise.  In this white paper, TrialCard discusses the steps it has taken to expand its Pharmacy Fraud Monitoring Service, which identifies fraud and greatly reduces the rei … Read More »

Despite all the advances in science, medicine and technology, clinical trials are stuck in a rut: Most have trouble meeting enrollment targets. It’s an analog problem in a digital world. You could find hundreds, maybe thousands, of reasons why a specific study is slow to enr … Read More »

Healthcare markets are becoming more competitive and more complex, so how is this impacting the way pharma launches products and services? In this in-depth white paper, we explore the challenges and opportunities for pharma companies launching products and services today. By … Read More »

Medical storytelling differentiates your key messages by framing them into a narrative that is both compelling and compliant. It elevates data-driven content from informative to transformative — engaging, educating, and ultimately changing behavior. Understand the science be … Read More »

Parkinson’s Disease (PD), a common neurodegenerative disorder of the central nervous system, is the subject of much R&D in the Life Sciences industry, given that there are currently no disease-modifying agents on the market. Yet, the therapeutic area poses significant ch … Read More »

The 340B patient definition requires that the hospital has established a relationship with the individual such that the hospital maintains records of the individual’s health care; and the individual receives health care services from a health care professional who is either … Read More »

On October 15, the Trump Administration published a proposed rule that, if finalized, would require prescription drug makers to include drug price information in broadcast advertising. This controversial proposal would implement an idea first broached in the Administration’s … Read More »

Sponsors and CROs want to be patient-centric, but it’s hard to know what exactly to do to improve the patient experience, or what the measurable benefits of keeping patients more engaged really are. In this whitepaper, you’ll learn what patient engagement actually means and … Read More »

Technology is transforming clinical drug development. In the rare disease space, clinical drug development is moving away from traditional approaches that rely on patients to travel long distances to clinical sites and toward a more patient-focused paradigm. This new paradig … Read More »

As genetic testing becomes increasingly common as an integral part of clinical development programs, understanding the key terms and definitions is essential for all members of research and clinical development teams. Download this glossary of commonly used terms in Precisio … Read More »

Oral anticancer medicines are well established in healthcare, shifting greater responsibility on the patient to self-manage their treatment. Yet, a recent literature review showed adherence rates to oral anticancer treatments are as low as 40%. While there is a range of supp … Read More »

Clinical trials in rare diseases present unique challenges unseen in trials for more common conditions. Rare disease patient populations are inherently small, and prospective participants are widely dispersed. Likewise, the number of clinical research sites with such special … Read More »

Good insight gives you the tools to create innovative products and services that meet customers’ needs at the point of need, transforming lives. However, many organisations find distilling large swathes of data into meaningful insights challenging. Download the white paper t … Read More »

In the majority of clinical trials we undertake, the consent process is fairly straightforward; however, complex situations do arise. Pediatric clinical trials present unique challenges, as do those in patients who lack legal competence. In the instance of a mentally impaire … Read More »

Optimize the value of engagements with advanced analytics and proprietary, technology-enabled identification and profiling techniques.

The impact of innovation is evident across a number of industries but has not been fully realized within the pharmaceutical industry. With rising R&D costs, a more crowded marketplace and increased focus on value demonstration, developers face mounting pressure in bringi … Read More »

Over the years, studies have been conducted to ascertain the cost of research and development (“R&D”) required to bring a new drug to market. Experts disagree on the exact amount, but the consensus is that the figure is in the hundreds of millions to over a billion dolla … Read More »

By Mike Davitian, Haley Fitzpatrick, Grace Perkins, Tara Breton, Remy Denzler, and Dean Giovanniello In business, we all know it is important to make a good first impression, but in pharma, that may be understating it: an effective commercial launch may swing cumulative reve … Read More »

Who is an Influencer? Who is a Key Opinion Leader (KOL)? These questions used to be easily answered with clear data and research tools. While additional dimensions always existed, they were hard to discern. And now, social and digital activity have expanded the definition of … Read More »

This installment of our whitepaper series discusses what it means to engage patients effectively, and why digital behavioral change interventions (DBCIs) need to ensure a strong patient engagement strategy is at its core. Request the full Exclusive whitepaper which includes … Read More »

As the complexity of precision oncology trials increase, drug developers are facing the paradox of patient scarcity in the presence of data abundance. Using the right technologies can help to solve this paradox. Read our white paper to learn more.  

Disruptive Innovation in the Life Science Industry At a panel session hosted by ICON early in 2018, senior executives from leading pharma companies shared their views on ‘Disruptive Innovation’. The session was chaired by Nuala Murphy (President, Clinical Research Services, … Read More »

In a reported effort to reduce health plan spend for specialty drugs, pharmacy benefit managers have begun promoting “co-pay accumulator” programs to health plan sponsors. The effect of these programs is often to shift much of the cost burden for expensive specialty drugs to … Read More »

Research sites are critically important to the development and testing of new therapies. They help bring new treatments to patients—and provide the reliable data that stops the development of unsuccessful projects. While active, organized sites are essential to support the c … Read More »

Recruitment materials are the first introduction to a study for potential participants, and post-consent materials can influence decisions about continued participation. It is important to adhere to the principles of subject protection—that is, allowing subjects to make info … Read More »

BulletinHealthcare ran an analysis of their audience of verified physicians, and found that they can reach 40,000 physicians who work in teaching hospitals that do not allow pharma reps access. Download the whitepaper to see where.

TrialCard Addresses AB 265 On October 9, 2017, California Governor Jerry Brown signed AB 265 into law. This landmark piece of legislation modified the California Health and Safety Code to prohibit the “offering” of any discount, product voucher, or other out-of-pocket cost r … Read More »

As clinical trials become more complex and increasingly global, the problem of over-distributing expedited safety reports to investigative sites has reached the point that demands a solution. The excessive volume of safety reports can cause investigators to miss important re … Read More »